Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment

AIDS

Volumn 27, Issue 6, 2013, Pages 961-965

  Lamorde, Mohammed ^a,b   Byakika Kibwika, Pauline ^a,b,c   Mayito, Jonathan ^a   Nabukeera, Lillian ^a   Ryan, Mairin ^b   Hanpithakpong, Warunee ^d   Lefèvre, Gilbert ^e   Back, David J ^f   Khoo, Saye H ^f   Merry, Concepta ^a,b,g  

^a MAKERERE UNIVERSITY   (Uganda)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Infectious Diseases Network for Treatment and Research in Africa   (Uganda)

^d MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIHYDROARTEMISININ; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LONGITUDINAL STUDY; LUNG TUBERCULOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OPPORTUNISTIC INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UGANDA;

ADULT; ANTIMALARIALS; ANTITUBERCULAR AGENTS; ARTEMISININS; DRUG ANTAGONISM; ETHANOLAMINES; FEMALE; FLUORENES; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; RIFAMPIN; TUBERCULOSIS; UGANDA;

EID: 84876398361     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835cae3b     Document Type: Article

References (14)

1. Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 2008; 62:872- 878.
2. World Health Organization. World malaria report. Geneva: World Health Organization, 2010. Available at http://www.who.int/malaria/world-malaria- report-2010/en/index.html.Lastaccessed19/04/2011.
3. World Health Organization. Treatment of tuberculosis. Guidelines. Geneva: World Health Organization, 2010. WHO/HTM/TB/2009.420WHO/HTM/TB/2009.420.
4. German PI, Aweeka FT. Clinical pharmacology of artemisininbased combination therapies. Clin Pharmacokinet 2008; 47:91- 102.
5. Coartem (artemether/lumefantrine) tablets. Full prescribing information. Revised August 2012. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936.
6. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether R benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46:553-561.
7. Oesch F, Arand M, Benedetti MS, Castelli MG, Dostert P. Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver. J Antimicrob Chemother 1996; 37:1111-1119.
8. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet 1999; 37:105-125.
9. Hanpithakpong W, Kamanikom B, Singhasivanon P, White NJ, Day NP, Lindegardh N. A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma. Bioanalysis 2009; 1:37-46.
10. Annerberg A, Singtoroj T, Tipmanee P, White NJ, Day NP, Lindegardh N. High throughput assay for the determination of lumefantrine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 822:330-333.
11. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 version). Geneva: World Health Organization, 2010.
12. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67:2213-2221.
13. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-467.
14. Zarocostas J. WHO unveils plan to stop artemisinin resistance 'dead in its tracks'. BMJ 2011; 342:d211.